Patent ID: 7160891

Claim:
A method for the treatment of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis in a warm-blooded animal in need thereof which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I wherein: m is 1 and the R 1 group is located at the 7-position and is selected from methoxy, benzyloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy, 2-[(2S)-2-(N,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy, 3-methylsulphonylpropoxy, 2-(4-pyridyloxy)ethoxy, 2-pyridylmethoxy, 3-pyridylmethoxy and 4-pyridylmethoxy; the Q 1 -Z- group is selected from tetrahydropyran-4-yloxy, N-methylpyrrolidin-3-yloxy, 4-piperidinyloxy, N-methylpiperidin-4-yloxy, cyclopentyloxy and cyclohexyloxy; each of R 2 and R 3 is hydrogen; and Q 2 is an aryl group of formula Ia wherein G 1 is selected from chloro, bromo, trifluoromethyl, methyl, methoxy and pyrrolidin-1-yl, G 2 is hydrogen, G 3 is selected from hydrogen and chloro, G 4 is methoxy, and G 5 is hydrogen, or G 1 and G 2 together form a group of formula:— —CH═CH—CH═C(Cl)—, —O—CH═C(Cl)— or —O—CH 2 —O—, each of G 3 and G 4 is hydrogen, and G 5 is hydrogen or chloro; or a pharmaceutically-acceptable acid-addition salt thereof.